Chugai Pharmaceutical Co., Ltd. (4519.T) JPX
9,255.00
+255(+2.83%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
9,255.00
+255(+2.83%)
Currency In JPY
Address
Nihonbashi Mitsui Tower
Tokyo, 103-8324
Japan
Phone
81 3 3281 6611
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
5026
First IPO Date
January 04, 2000
| Name | Title | Pay | Year Born |
| Osamu Okuda | President, CEO & Chairman | 282M | 1963 |
| Kaori Ouchi | EVP and Head of Risk & Compliance Department | 0 | N/A |
| Shinji Hidaka | Executive Vice President | 0 | N/A |
| Tetsuya Yamaguchi | Executive Vice President | 0 | N/A |
| Tomoyuki Igawa | VP & Head of Research Division | 0 | N/A |
| Junichi Takano | Head of Marketing & Sales Division | 0 | N/A |
| Iwaaki Taniguchi | Executive Vice President, Head of Finance Supervisory Division, Chief Financial Officer & Director | 0 | 1966 |
| Kosuke Iijima | Head of PHC Solution Department | 0 | N/A |
| Yoshiyuki Yano | Executive Vice President | 0 | N/A |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | 0 | N/A |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.